INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers
Alec G. Trub1, John E. Bisi1, Catherine Dietrich2, Michael Taylor, Jay C. Strum1, Shom Goel2, Patrick J. Roberts1 1Incyclix Bio, Durham, NC, United States, 2The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
See the Publication >
